Nectin-4 is widely expressed in head and neck squamous cell carcinoma
暂无分享,去创建一个
[1] Y. Oda,et al. Nectin Cell Adhesion Molecule 4 (NECTIN4) Expression in Cutaneous Squamous Cell Carcinoma: A New Therapeutic Target? , 2021, Biomedicines.
[2] Jianjun Gao,et al. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction , 2021, Frontiers in Oncology.
[3] Yoon Park,et al. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity , 2021, Pharmaceuticals.
[4] S. Sridhar,et al. Enfortumab Vedotin in urothelial cancer , 2020, Therapeutic advances in urology.
[5] C. R. Leemans,et al. Head and neck squamous cell carcinoma , 2020, Nature Reviews Disease Primers.
[6] E. Heath,et al. The biology and rationale of targeting nectin-4 in urothelial carcinoma , 2020, Nature Reviews Urology.
[7] G. Netto,et al. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma , 2020, International journal of molecular sciences.
[8] B. Seliger,et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity , 2020, Journal for immunotherapy of cancer.
[9] David C. Smith,et al. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Fisher,et al. Head and Neck Squamous Cell Carcinoma , 2020, Definitions.
[11] Xiaolong Lin,et al. The Prognostic Role of Expression of Nectin-4 in Esophageal Cancer , 2019, Medical science monitor : international medical journal of experimental and clinical research.
[12] K. Hanna. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma , 2019, Drugs.
[13] T. Day,et al. Impact of PD‐L1 expression and human papillomavirus status in anti‐PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma—Systematic review and meta‐analysis , 2019, Head & neck.
[14] P. Lou,et al. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions , 2019, Head & neck.
[15] C. Ng,et al. Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer , 2019, Front. Med..
[16] M. Galsky,et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Harrington,et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) , 2019, Journal of Immunotherapy for Cancer.
[18] A. Rich,et al. Human papillomavirus and oral and oropharyngeal carcinoma: the essentials , 2018, Australian dental journal.
[19] Qingfeng Ni,et al. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. , 2018, Oncology letters.
[20] R. Ferris,et al. Immunotherapy for Head and Neck Squamous Cell Carcinoma , 2018, Current Oncology Reports.
[21] Ruud H. Brakenhoff,et al. The molecular landscape of head and neck cancer , 2018, Nature Reviews Cancer.
[22] V. Servois,et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] G. Kristiansen,et al. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. , 2017, Oncotarget.
[24] A. Skubitz,et al. The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate , 2016, Oncotarget.
[25] F. Bertucci,et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[27] D. Stover,et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. , 2016, Cancer research.
[28] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[29] R. Verhaak,et al. The landscape and therapeutic relevance of cancer-associated transcript fusions , 2014, Oncogene.
[30] Petar Stojanov,et al. Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas , 2014, Clinical Cancer Research.
[31] Y. Takai,et al. The role of nectins in different types of cell–cell adhesion , 2012, Journal of Cell Science.
[32] S. Kalloger,et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. , 2010, American journal of clinical pathology.
[33] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[34] Jun Miyoshi,et al. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation , 2008, Nature Reviews Molecular Cell Biology.
[35] M. Karamouzis,et al. Head and neck cancer , 2008, The Lancet.
[36] A. Cmelak,et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.
[37] P. Dubreuil,et al. Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. , 2002, The Journal of biological chemistry.
[38] P. Dubreuil,et al. Nectin4/PRR4, a New Afadin-associated Member of the Nectin Family That Trans-interacts with Nectin1/PRR1 through V Domain Interaction* , 2001, The Journal of Biological Chemistry.
[39] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.